DOCSLIB.ORG

Therapeutic Potential of B-1A Cellsin COVID-19 Monowar Aziz , Max

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Therapeutic Potential of B-1A Cellsin COVID-19 Monowar Aziz , Max SHOCK: Publish Ahead Print DOI: 10.1097/SHK.0000000000001610 Therapeutic Potential of B-1a Cellsin COVID-19 Monowar Aziz1*, Max Brenner1,2, Ping Wang1,2,3* 1Center for Immunology and Inflammation, The Feinstein Institutes for Medical Research, 09/22/2020 on BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3XGJiJSDa6kJtrA8GTJF1rNYg2oN5/iB8BU7ukdhpX3U= by http://journals.lww.com/shockjournal from Downloaded Downloaded Manhasset, NY from 2 http://journals.lww.com/shockjournal Department of Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY 3Department of Surgery, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3XGJiJSDa6kJtrA8GTJF1rNYg2oN5/iB8BU7ukdhpX3U= Running title:B-1a cells and COVID-19 Competing financial and/or non-financial interests: All authors declared that they have no competing interests. *Addresses for correspondence: Ping Wang, MD Professor and Chief Scientific Officer (CSO) The Feinstein Institutes for Medical Research 350 Community Dr., Manhasset, NY 11030 Tel: (516) 562-3411 Fax: (516) 562-2396 E-mail: [email protected] on Monowar Aziz, PhD 09/22/2020 Assistant Professor Center for Immunology and Inflammation The Feinstein Institutes for Medical Research 350 Community Dr., Manhasset, NY 11030 E-mail: [email protected] Copyright © 2020 by the Shock Society. Unauthorized reproduction of this article is prohibited. Abstract Coronavirus disease 2019 (COVID-19) is a life-threatening respiratory illnesscaused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Its clinical presentation can vary from the asymptomatic state to acute respiratory distress syndrome (ARDS) and multi- organ dysfunction. Due to ourinsufficient understanding of its pathophysiology and lack of effective treatment,the morbidity and mortality ofsevere COVID-19 patients are high. Patients with COVID-19developARDSfueled byexaggerated neutrophil influx into the lungs and cytokine storm. B-1a cells represent a unique subpopulation of B lymphocytescritical for circulating natural antibodies, innate immunity,andimmunoregulation. These cells spontaneously produce natural IgM, interleukin (IL)-10, and granulocyte-monocytecolony stimulating factor (GM-CSF). Natural IgM neutralizes viruses and opsonizes bacteria, IL-10 attenuates the cytokine storm, and GM-CSF induces IgM production by B-1a cells in an autocrine manner. Indeed, B-1a cells have been shown to ameliorate influenza virus infection,sepsis, and pneumonia, all of which are similar to COVID-19. The recentdiscovery of B-1a cells in humans further reinforces their potentially critical role in the immune response against SARS-CoV-2 and their anticipated translational applications againstviral and microbial infections. Given that B-1a cells protect againstARDS via immunoglobulin production and theanti-COVID-19 effects ofconvalescent plasmatreatment, we recommend that studies be conducted to further examine the role of B-1a cells in the pathogenesis of COVID-19 and explore theirtherapeutic potential to treat COVID-19 patients. Key words: COVID-19; SARS-CoV-2; B-1a cells; IL-10; IgM; Neutrophils; ARDS;Sepsis Copyright © 2020 by the Shock Society. Unauthorized reproduction of this article is prohibited. Introduction Coronavirus disease 2019 (COVID-19) is an infectious disease caused by therecently identified and highly contagious severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2)(1). COVID-19 predominantly affectsthe respiratory systembecause the virus binds to cells expressingthe angiotensin-converting enzyme 2 (ACE2), which is abundantin the surface of type II alveolar cells of the lungs(2, 3). The virus uses itstransmembrane spike (S) glycoprotein to connect to ACE2 and penetrate the host cellwhere ithijacksthe cell machineryto multiply (2, 3).Many patients are asymptomatic or show only flu-like symptoms, but a substantial subset of COVID-19 patients develop severe pneumonia that often progresses toacute respiratory distress syndrome (ARDS)fueled by excessive neutrophilinfiltration and uncontrolled production of pro- inflammatory cytokines in the lungs(4-7). At the moment, the treatmentfor patients with COVID-19 is essentially supportive and symptomatic. There is a long list of drugs being evaluated and clinical trials being carried out(8), but none of them has yet proven to be a game changerfor patients withCOVID-19.Promising treatments include monoclonal antibodies against pro-inflammatory cytokines (8), immunoglobulin therapy,andantibody-containing convalescent plasmafrom recovered patients (8, 9). B-1a cells consist of a unique subset of B lymphocytes which play an early and key role in the innate immune response against viral, bacterial, and acute inflammatory diseases(10). These cells release polyreactivenatural IgM which non-specifically recognizesand neutralizes microbes(10-12). These cells also spontaneously produce the anti-inflammatory cytokines interleukin (IL)-10 and IL-35 and the immune bolsteringfactor granulocyte-monocyte colony stimulating factor (GM-CSF)(10, 13-15).B-1acells andsubpopulationswere originally described Copyright © 2020 by the Shock Society. Unauthorized reproduction of this article is prohibited. in the mouse and have also beenrecently identified in humans (16). B-1a cells ameliorate acute viral and bacterial infections in rodent models of influenza, polymicrobial sepsis, and pneumonia(10). B-1a cell therapyis able to mitigate the progression of these infections to ARDS,raising the possibility that B-1a cell therapymay alsoameliorate ARDS associated with COVID-19. Here, we review the protective effects ofB-1a cells in animal models of ARDScaused by viral and bacterialinfections with the caveat that sepsis and influenza may not accurately reflect the immune processes of COVID-19. We compare the pathophysiological and clinical aspects between bacterial sepsis and severe COVID-19 in Tables 1 and 2. Weanalyze the literature on B- 1a cells with a focus on the excessive neutrophil infiltration, abnormal neutrophil function, and the cytokine storm which have been described in numerous studies of patients with COVID-19. By comparing the existing B-1a cell literature and recent advances in the pathogenesis of COVID-19, we propose a novel perspective suggesting that treatment with B-1a cells may benefit patients with COVID-19.Since many clinical trials in sepsis have failed and almost no drug has yet been developed to treat sepsis patients,we acknowledge an obstacle of implementation of B-1a cells as a therapeutic candidate in COVID-19 because the beneficial outcomes of B-1a cells as reported here were mainly built upon sepsis data.For designing and conducting immunotherapies for COVID-19, the lessons learned from the sepsis clinical trials should be reminisced(17). COVID-19complications and pathophysiology While many infected individuals develop mild or moderate symptoms, a significant fraction of patients develop severe pneumonia, ARDS, multi-organ failure, and septic shock, not rarely resulting in death(4, 18). Cardiovascular complications may include heart failure, arrhythmias, Copyright © 2020 by the Shock Society. Unauthorized reproduction of this article is prohibited. myocarditis, and hypercoagulability(19). In addition, COVID-19 patients may sometimes develop liver injuryand acute kidney injury (20, 21). Its related neurologic manifestations include seizure, stroke, and encephalitis(22). The elderly are particularly vulnerable to severe SARS- CoV-2 infection, with a mortality rate higher than that of younger individuals, which may be due to a combination of immune senescence and the presence of co-morbidities(23, 24).However, following SARS-CoV-2 infection, patients of all ages can develop COVID-19, including children who sometimes developa severe systemic inflammation that can be lethal (25). SARS-CoV-2is a membrane-enveloped positive sense single-stranded RNAvirus of 50- 200 nm in diameter. It has four structural proteins: thespike(S), envelope (E), membrane (M), and nucleocapsid (N) proteins(26). The S protein has strong affinity for ACE2 on human cells,which it uses asa receptor to attach to and penetrate host cells, where it multiplies intonumerous copies(2).The higher expression of ACE2 in lung, heart, ileum, and kidney cells explains why these organs are affected more than others (26, 27). After intracellular replication and maturation, the host cell bursts releasing the virionsand starting a new cycle of infection(26). As cells rupture (lytic release), it is speculated that they also release intracellular components, such as extracellular cold-inducible RNA binding protein (eCIRP), double-stranded DNA, histones, and high mobility group box 1 (HMGB1)(28). Nearby cells get activated by the viral single-stranded RNA and proteins via pathogen-associated molecular pattern (PAMP) receptors, as well as by the ruptured cell contents viadamage- associated molecular pattern (DAMP) receptors(28, 29). Downstream signaling from these receptors leads to the release chemokines, antiviral cytokines, and pro-inflammatory cytokines and other mediators. As a result, patients with severe COVID-19 havea cytokine storm characterized byelevated levels of IL-2, IL-7, IL-6, tumor necrosis factor-α (TNF-α), interferon-γ Copyright © 2020 by the Shock Society. Unauthorized reproduction of this article is prohibited. inducible protein 10, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1-α(4, 30).Additionally,
Load more

Recommended publications
  • Khan CV 9-4-20
    CURRICULUM VITAE DAVID A. KHAN, MD University of Texas Southwestern Medical Center 5323 Harry Hines Boulevard Dallas, TX 75390-8859 (214) 648-5659 (work) (214) 648-9102 (fax) [email protected] EDUCATION 1980 -1984 University of Illinois, Champaign IL; B.S. in Chemistry, Magna Cum Laude 1984 -1988 University of Illinois School of Medicine, Chicago IL; M.D. 1988 -1991 Good Samaritan Medical Center, Phoenix AZ; Internal Medicine internship & residency 1991-1994 Mayo Clinic, Rochester MN; Allergy & Immunology fellowship PROFESSIONAL EXPERIENCE 1994 -2001 Assistant Professor of Internal Medicine, UT Southwestern 1997 -1998 Co-Director, Allergy & Immunology Training Program 1998 - Director, Allergy & Immunology Training Program 2002- 2008 Associate Professor of Internal Medicine, UT Southwestern 2008-present Professor of Medicine, UT Southwestern AWARDS/HONORS 1993 Allen & Hanburys Respiratory Institute Allergy Fellowship Award 1993 Von Pirquet Award 2001 Outstanding Teacher 2000-2001 UTSW Class of 2003 2004 Outstanding Teacher 2003-2004 UTSW Class of 2006 2005 Outstanding Teacher 2004-2005 UTSW Class of 2007 2006 Daniel Goodman Lectureship, ACAAI meeting 2007 Most Entertaining Teacher 2006-2007 UTSW Class of 2009 2008 Stanislaus Jaros Lectureship, ACAAI meeting 2009 Outstanding Teacher 2007-2008 UTSW Class of 2010 2011 John L. McGovern Lectureship, ACAAI meeting 2012 I. Leonard Bernstein Lecture, ACAAI meeting 2014 Distinguished Fellow, ACAAI meeting 2015 Elliot F. Ellis Memorial Lectureship, AAAAI meeting 2015 Bernard Berman Lectureship,
    [Show full text]
  • Newborn Screening for Severe Combined Immunodeficiency And
    Newborn screening for SCID and related forms of Primary Immunodeficiency Michael Keller, MD Division of Allergy and Immunology Aims To review the epidemiology and possible presentations of primary immunodeficiency disorders. To learn about the TREC newborn screening assay, and what to do with a positive result. Speaker Disclosures No disclosures to declare. Case: 10 month old girl Ex FT infant, poor weight and chronic diarrhea since 2 months of age. No prior known infections, negative FH. Initial workup CBC: CMP: Na: 135 WBC: 5.6 K: 3.9 Hb: 11.3 Cl: 104 Hct: 34.1 CO2: 24 MCV: 79.1 BUN: 4 Plt: 386 Cr: 0.2 ANC: 2055 Glu: 70 Total protein: 4.9 ALC: 3102 Albumin: 3.0 Eos: 0.2% Alk Phos: 126 Monos: 6.9% ALT: 84 AST: 87 Phos: 4.8 Mg: 2.3 GGT: 17 Differential . Primary GI disease . IBD, allergic enterocolitis, . GI channelopathy . Metabolic disorder or CF . Newborn screening catches many but not all . Chronic infection . HIV . Immune disorder Further testing • Stool testing: negative for norovirus, enterovirus, parechovirus, adenovirus, O&P, culture • Negative CMV, EBV PCRs (blood) • Normal fecal elastase (434) • Positive Rotavirus Antigen EIA Further testing Hypogammaglobulinemia No vaccine responses Further testing Lymphocyte Flow Cytometry Marker Value Normal range (cells/mcl) (cells/mcl) CD3+ (T-cells) 242 1600-6700 CD3/CD4+ 86 1000-4600 CD3/CD8+ 15 400-2100 CD4/CD45RA+ 61 500-1100 CD4/CD45RO+ 57 150-600 CD16/56+, CD3- (NK cells) 223 200-1200 CD19+ (B-cells) 1735 600-2700 Profound T-cell Lymphocytopenia Diagnosis Dx: Severe combined immunodeficiency Epidemiology: Primary immunodeficiency Over 200+ known congenital immunologic defects • In total, primary immunodeficiency is thought to occur as frequent as 1 in 5000.
    [Show full text]
  • Advances in Dental Research
    Advances in Dental Research http://adr.sagepub.com/ The Association Between Immunodeficiency and the Development of Autoimmune Disease J.W. Sleasman ADR 1996 10: 57 DOI: 10.1177/08959374960100011101 The online version of this article can be found at: http://adr.sagepub.com/content/10/1/57 Published by: http://www.sagepublications.com On behalf of: International and American Associations for Dental Research Additional services and information for Advances in Dental Research can be found at: Email Alerts: http://adr.sagepub.com/cgi/alerts Subscriptions: http://adr.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav Downloaded from adr.sagepub.com by guest on July 18, 2011 For personal use only. No other uses without permission. THE ASSOCIATION BETWEEN IMMUNODEFICIENCY AND THE DEVELOPMENT OF AUTOIMMUNE DISEASE J.W. SLEASMAN aradoxically, individuals with primary or acquired immunodeficiency disease have an increased Division of Pediatric Immunology and Allergy incidence of autoimmunity. Human primary University of Florida College of Medicine immunodeficiency disease can be classified as Box 100296, 1600 SW Archer Road P disorders of cell-mediated immunity, humoral immunity, Gainesville, Florida 32610-0296 phagocytic cell function, and the complement system (Barrett and Sleasman, 1990). Cell-mediated and humoral immunity Adv Dent Res 10(l):57-61, April, 1996 comprise the adaptive arm of the immune response, which is antigen-specific and confers immunologic memory. The innate immune response, which is antigen-nonspecific, is Abstract—There is a paradoxical relationship between composed of phagocytic cells and the inflammatory peptides. immunodeficiency diseases and autoimmunity. While not all Not all individuals with inherited immunodeficiency develop individuals with immunodeficiency develop autoimmunity, autoimmunity, nor are all individuals with autoimmune nor are all individuals with autoimmunity immunodeficient, disease immunodeficient.
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • Current Perspectives on Primary Immunodeficiency Diseases
    Clinical & Developmental Immunology, June–December 2006; 13(2–4): 223–259 Current perspectives on primary immunodeficiency diseases ARVIND KUMAR, SUZANNE S. TEUBER, & M. ERIC GERSHWIN Division of Rheumatology, Allergy and Clinical Immunology, Department of Internal Medicine, University of California at Davis School of Medicine, Davis, CA, USA Abstract Since the original description of X-linked agammaglobulinemia in 1952, the number of independent primary immunodeficiency diseases (PIDs) has expanded to more than 100 entities. By definition, a PID is a genetically determined disorder resulting in enhanced susceptibility to infectious disease. Despite the heritable nature of these diseases, some PIDs are clinically manifested only after prerequisite environmental exposures but they often have associated malignant, allergic, or autoimmune manifestations. PIDs must be distinguished from secondary or acquired immunodeficiencies, which are far more common. In this review, we will place these immunodeficiencies in the context of both clinical and laboratory presentations as well as highlight the known genetic basis. Keywords: Primary immunodeficiency disease, primary immunodeficiency, immunodeficiencies, autoimmune Introduction into a uniform nomenclature (Chapel et al. 2003). The International Union of Immunological Societies Acquired immunodeficiencies may be due to malnu- (IUIS) has subsequently convened an international trition, immunosuppressive or radiation therapies, infections (human immunodeficiency virus, severe committee of experts every two to three years to revise sepsis), malignancies, metabolic disease (diabetes this classification based on new PIDs and further mellitus, uremia, liver disease), loss of leukocytes or understanding of the molecular basis. A recent IUIS immunoglobulins (Igs) via the gastrointestinal tract, committee met in 2003 in Sintra, Portugal with its kidneys, or burned skin, collagen vascular disease such findings published in 2004 in the Journal of Allergy and as systemic lupus erythematosis, splenectomy, and Clinical Immunology (Chapel et al.
    [Show full text]
  • Prevalence and Pathogenicity of Autoantibodies in Patients with Idiopathic CD4 Lymphopenia
    Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia Ainhoa Perez-Diez, … , Richard Siegel, Irini Sereti J Clin Invest. 2020;130(10):5326-5337. https://doi.org/10.1172/JCI136254. Clinical Medicine Autoimmunity Immunology Graphical abstract Find the latest version: https://jci.me/136254/pdf CLINICAL MEDICINE The Journal of Clinical Investigation Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia Ainhoa Perez-Diez,1 Chun-Shu Wong,1 Xiangdong Liu,1 Harry Mystakelis,1 Jian Song,2 Yong Lu,2 Virginia Sheikh,1 Jeffrey S. Bourgeois,1 Andrea Lisco,1 Elizabeth Laidlaw,1 Cornelia Cudrici,3 Chengsong Zhu,4 Quan-Zhen Li,4,5 Alexandra F. Freeman,6 Peter R. Williamson,7 Megan Anderson,1 Gregg Roby,1 John S. Tsang,2,8 Richard Siegel,3 and Irini Sereti1 1HIV Pathogenesis Section, Laboratory of Immunoregulation, and 2Multiscale Systems Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), and 3Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA. 4Microarray Core Facility and 5Department of Immunology and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 6Laboratory of Clinical and Molecular Immunology and 7Translational Mycology Section, Laboratory of Clinical and Molecular Immunology, NIAID, and 8Trans-NIH Center for Human Immunology, NIH, Bethesda, Maryland, USA. BACKGROUND. Idiopathic CD4 lymphopenia (ICL) is defined by persistently low CD4+ cell counts (<300 cells/μL) in the absence of a causal infection or immune deficiency and can manifest with opportunistic infections. Approximately 30% of ICL patients develop autoimmune disease.
    [Show full text]
  • Patient & Family Handbook
    Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SIXTH EDITION COPYRIGHT 1987, 1993, 2001, 2007, 2013, 2019 IMMUNE DEFICIENCY FOUNDATION Copyright 2019 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. The Immune Deficiency Foundation Patient & Family Handbook may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA; or by telephone at 800-296-4433. Immune Deficiency Foundation Patient & Family Handbook For Primary Immunodeficiency Diseases 6th Edition The development of this publication was supported by Shire, now Takeda. 110 West Road, Suite 300 Towson, MD 21204 800.296.4433 www.primaryimmune.org [email protected] Editors Mark Ballow, MD Jennifer Heimall, MD Elena Perez, MD, PhD M. Elizabeth Younger, Executive Editor Children’s Hospital of Philadelphia Allergy Associates of the CRNP, PhD University of South Florida Palm Beaches Johns Hopkins University Jennifer Leiding,
    [Show full text]
  • Idiopathic CD4 T Cell Lymphocytopenia: a Case of Overexpression of PD-1/PDL-1 and CTLA-4
    Case Report Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4 Gaurav Kumar 1,2,* , Heidy Schmid-Antomarchi 2 , Annie Schmid-Alliana 2 , Michel Ticchioni 2 and Pierre-Marie Roger 2,3,4,5 1 Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA 2 Unité 576, Institut National de la Santé et de la Recherche Médicale, Hôpital de l’Archet I, 151 Route de Saint-Antoine, 06200 Nice, France; [email protected] (H.S.-A.); [email protected] (A.S.-A.); [email protected] (M.T.); [email protected] (P.-M.R.) 3 Laboratoire d’Immunologie, Hôpital de l’Archet, Centre Hospitalier Universitaire de Nice, 151 Route de Saint-Antoine, 06200 Nice, France 4 Infectiologie, Centre Hospitalier Universitaire de la Guadeloupe, Pointe-à-Pitre/Abymes, Route de Chauvel, Les Abymes, 97139 Guadeloupe, France 5 Faculté de Médecine, Université des Antilles, 97157 Pointe-à-Pitre, France * Correspondence: [email protected]; Tel.: +1-405-271-2907 Abstract: Idiopathic CD4 T cell lymphocytopenia (ICL) is a rare entity characterized by CD4 T cell count of <300 cells/mm3 along with opportunistic infection for which T cell marker expression remains to be fully explored. We report an ICL case for which T lymphocyte phenotype and its costimulatory molecules expression was analyzed both ex vivo and after overnight stimulation through CD3/CD28. The ICL patient was compared to five healthy controls. We observed higher expression of inhibitory molecules PD-1/PDL-1 and CTLA-4 on CD4 T cells and increased regulatory Citation: Kumar, G.; T cells in ICL, along with high activation and low proliferation of CD4 T cells.
    [Show full text]
  • Absolute Lymphocyte Count Is a Prognostic Marker in Covid-19: a Retrospective Cohort Review
    Received: 12 May 2020 | Revised: 26 May 2020 | Accepted: 21 June 2020 DOI: 10.1111/ijlh.13288 ORIGINAL ARTICLE Absolute lymphocyte count is a prognostic marker in Covid-19: A retrospective cohort review Jason Wagner1 | Andrew DuPont2 | Scott Larson2 | Brooks Cash2 | Ahmad Farooq2,3 1Department of Internal Medicine, University of Texas Health Science Center at Abstract Houston, Houston, TX, USA Introduction: Prognostic factors are needed to aid clinicians in managing Covid-19, 2 Department of Internal Medicine, Division a respiratory illness. Lymphocytopenia has emerged as a simply obtained laboratory of Gastroenterology, Hepatology and Nutrition, University of Texas Health value that may correlate with prognosis. Science Center at Houston, Houston, TX, Methods: In this article, we perform a retrospective cohort review study on patients USA 3Department of Internal Medicine, Division admitted to one academic hospital for Covid-19 illness. We analyzed basic demo- of Gastroenterology and Hepatology, Duke graphic, clinical, and laboratory data to understand the relationship between lym- University, Durham, NC, USA phocytopenia at the time of hospital admission and clinical outcomes. Correspondence Results: We discovered that lymphocyte count is lower (P = .01) and lymphocytope- Ahmad Farooq, Department of Internal Medicine, Division of Gastroenterology, nia more frequent by an odds ratio of 3.40 (95% CI: 1.06-10.96; P = .04) in patients Hepatology and Nutrition, University of admitted to the Intensive Care Unit (ICU), a marker of disease severity, relative to Texas Health Science Center at Houston, 6431 Fannin, MSB 1.150. Houston, TX those who were not. We additionally find that patients with lymphocytopenia were 77030, USA.
    [Show full text]
  • M. Kansasii Pulmonary Disease in Idiopathic CD4+ T-Lymphocytopenia
    Eur Respir J, 1996, 9, 1754–1756 Copyright ERS Journals Ltd 1996 DOI: 10.1183/09031936.96.09081754 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 CASE STUDY M. Kansasii pulmonary disease in idiopathic CD4+ T-lymphocytopenia G. Anzalone*, M. Cei**, A. Vizzaccaro+, B. Tramma*, A. Bisetti† M. Kansasii pulmonary disease in idiopathic CD4+ T-lymphocytopenia. G. Anzalone, *Centro Cardiorespiratorio I.N.A.I.L., Firenze, M. Cei, A. Vizzaccaro, B. Tramma, A. Bisetti. ERS Journals Ltd 1996. Italy. **Centro Trasfusionale Marine Militare, ABSTRACT: Cases of patients with markedly depressed CD4+ T-lymphocyte counts, La Spezia, Italy. +Reparto I^Medicina Ospe- with or without opportunistic infections, in the absence of any evidence of human dale Principale Marina Militare, La Spezia, Italy. +I^Clinica Tisiopneumologica Uni- immunodeficiency virus (HIV) have been described in recent years. In 1992, the versità di Roma, Italy. definition of "idiopathic CD4+ T-lymphocytopenia" was formulated by the Centers for Disease Control and Prevention (CDC) of Atlanta (USA). Correspondence: G. Anzalone, Centro Cardio- respiratorio I.N.A.I.L., Via Delle Porte The present case illustrates the occurrence of an unexplained Mycobacterium Nuove 61, 50144 - Firenze, Italy kansasii pneumonia in a white HIV-negative subject with a persistent depletion of CD4+ T-lymphocytes and suppression of cell-mediated immunity. Keywords: Human immunodeficiency idiopathic CD4+ T-lymphocytopenia To our knowledge, this is the first observation of idiopathic CD4+ T-lymphocyto- M. Kansasii penia with pulmonary mycobacteriosis due to Mycobacterium kansasii, and the sixth Mycobacteriosis case of this kind of immunodeficiency described in Italy. Received: August 25 1995 Eur Respir J., 1996, 9, 1754–1756.
    [Show full text]
  • Pulmonary Complications of Primary Immunodeficiencies
    PAEDIATRIC RESPIRATORY REVIEWS (2004) 5(Suppl A), S225–S233 Pulmonary complications of primary immunodeficiencies Rebecca H. Buckley° Departments of Pediatrics and Immunology, Duke University Medical Center, Durham, NC 27710, USA Summary In the fifty years since Ogden Bruton discovered agammaglobulinemia, more than 100 additional immunodeficiency syndromes have been described. These disorders may involve one or more components of the immune system, including T, B, and NK lymphocytes; phagocytic cells; and complement proteins. Most are recessive traits, some of which are caused by mutations in genes on the X chromosome, others in genes on autosomal chromosomes. Until the past decade, there was little insight into the fundamental problems underlying a majority of these conditions. Many of the primary immunodeficiency diseases have now been mapped to specific chromosomal locations, and the fundamental biologic errors have been identified in more than 3 dozen. Within the past decade the molecular bases of 7 X-linked immunodeficiency disorders have been reported: X-linked immunodeficiency with Hyper IgM, X-linked lymphoproliferative disease, X-linked agammaglobulinemia, X-linked severe combined immunodeficiency, the Wiskott–Aldrich syndrome, nuclear factor úB essential modulator (NEMO or IKKg), and the immune dysregulation polyendocrinopathy (IPEX) syndrome. The abnormal genes in X-linked chronic granulomatous disease (CGD) and properdin deficiency had been identified several years earlier. In addition, there are now many autosomal recessive immunodeficiencies for which the molecular bases have been discovered. These new advances will be reviewed, with particular emphasis on the pulmonary complications of some of these diseases. In some cases there are unique features of lung abnormalities in specific defects.
    [Show full text]
  • Apoptotic Depletion of CD4+ T Cells in Idiopathic CD4+ T Lymphocytopenia
    Apoptotic depletion of CD4+ T cells in idiopathic CD4+ T lymphocytopenia. J Laurence, … , F P Siegal, L Staiano-Coico J Clin Invest. 1996;97(3):672-680. https://doi.org/10.1172/JCI118464. Research Article Progressive loss of CD4+ T lymphocytes, accompanied by opportunistic infections characteristic of the acquired immune deficiency syndrome, ahs been reported in the absence of any known etiology. The pathogenesis of this syndrome, a subset of idiopathic CD4+ T lymphocytopenia (ICL), is uncertain. We report that CD4+ T cells from seven of eight ICL patients underwent accelerated programmed cell death, a process facilitated by T cell receptor cross-linking. Apoptosis was associated with enhanced expression of Fas and Fas ligand in unstimulated cell populations, and partially inhibited by soluble anti-Fas mAb. In addition, apoptosis was suppressed by aurintricarboxylic acid, an inhibitor of calcium- dependent endonucleases and proteases, in cells from four of seven patients, The in vivo significance of these findings was supported by three factors: the absence of accelerated apoptosis in persons with stable, physiologic CD4 lymphopenia without clinical immune deficiency; detection of serum antihistone H2B autoantibodies, one consequence of DNA fragmentation, in some patients; and its selectivity, with apoptosis limited to the CD4 population in some, and occurring among CD8+ T cells predominantly in those individuals with marked depletion of both CD4+ T lymphocytes linked to clinical immune suppression have evidence for accelerated T cell apoptosis in vitro that may be pathophysiologic and amenable to therapy with apoptosis inhibitors. Find the latest version: https://jci.me/118464/pdf Apoptotic Depletion of CD4؉ T Cells in Idiopathic CD4؉ T Lymphocytopenia Jeffrey Laurence,* Debashis Mitra,* Melissa Steiner,‡ David H.
    [Show full text]